TopArtSecondaryPage-1

Experimental Anti-IL-15 Antibody AMG 714 at ICDS

Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium

Oral Presentation to Highlight Rationale for the Study of AMG 714 in the Treatment of Celiac and Refractory Celiac Disease

Lebanon, NJ and Bethesda, MD, June 22, 2015 — Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will provide an oral presentation on an abstract related to the company’s lead product candidate, AMG 714, at the 16th International Coeliac Disease Symposium (ICDS), June 24, 2015, in Prague, Czech Republic.

The abstract, entitled, “Rationale for AMG 714, an anti-IL-15 mAb, in the treatment of celiac and refractory celiac disease,” is scheduled to be presented during the Novel Treatment session, on Wednesday, June 24, 2015, from 11:00am – 12:30pm CEST.

AMG 714 is a Phase 2, anti-IL-15 monoclonal antibody that Celimmune has licensed from Amgen (NASDAQ: AMGN) and is developing for the treatment of diet non-responsive celiac disease and Type II refractory celiac disease (RCD II), an in situ small bowel T cell lymphoma. IL-15 is a molecule produced by the immune system and intestinal cells that is considered to be a central regulator of celiac disease and a driver of lymphoma growth in RCD II. IL-15 has been shown to be one of the key factors in the loss of tolerance to food antigens, and it also is believed to be involved in Crohn’s disease and other autoimmune and inflammatory diseases.

About Celiac Disease

Celiac disease is a chronic hereditary systemic autoimmune disease triggered by gluten consumption. Celiac disease is characterized by damage to the lining of the small intestine, causing gastrointestinal dysfunction and debilitating symptoms. Nutritional malabsorption can lead to a failure to thrive in children and anemia and osteopenia in adults. Over the course of a lifetime, untreated or poorly managed celiac disease is often associated with deteriorating general health, multiple serious intestinal and extra-intestinal medical complications, and increased morbidity and mortality. Currently approximately 1% of Western and 0.5% of Asian populations suffer from celiac disease and the diagnosed prevalence is expected to increase dramatically with improved diagnostic tools and clinical awareness.

About Celimmune

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, began operating in February 2015 and is headquartered in Lebanon, NJ and Bethesda, MD. Celimmune will initially focus its distinctive core competence in translational medicine, immunotherapy clinical development and commercialization on combating celiac disease and other serious autoimmune diseases.

Celimmune Contact
Ashleigh Palmer
Celimmune LLC
+1.908.428.9136
apalmer@celimmune.com

Media Contact
Amy S. Wheeler
Tiberend Strategic Advisors, Inc.
+1.646.362.5750
awheeler@tiberend.com